Brief: Sprint Bioscience Completes Strategic Evaluation Of STK25 Program
16/04/2026 07:04
April 16 (Reuters) - Sprint Bioscience AB SPRINT.ST: COMPLETES STRATEGIC EVALUATION OF STK25 PROGRAM WITH EDDC EVALUATION DOES NOT SUPPORT PROCEEDING TO ANOTHER INFLAMMATORY INDICATION Source text: ID:nMFNj1DbZ Further company coverage: SPRINT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln
Brief: Sprint Bioscience Completes Strategic Evaluation Of STK25 Program
Brief: Sprint Bioscience Appoints Jenni Björnulfson As CFO
Brief: Sprint Bioscience Reports Positive Proof-Of-Concept Results From Program In CKD
Brief: Sprint Bioscience Reports Positive Results From The Vrk1 Program